CoChat

Understanding CD4+ T cells in autoimmune bullous diseases

Open access
Lee, A Yeong, Kim, Taehee, Kim, Jong Hoon · 2023 · Frontiers in Immunology

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Autoimmune bullous diseases (AIBDs) are a group of life-threatening blistering diseases caused by autoantibodies that target proteins in the skin and mucosa. Autoantibodies are the most important mediator in the pathogenesis of AIBDs, and various immune mechanisms contribute to the production of these pathogenic autoantibodies. Recently, significant progress has been made in understanding how CD4+ T cells drive autoantibody production in these diseases. Here, we review the critical role of CD4+ T cells in the production of pathogenic autoantibodies for the initiation and perpetuation of humoral response in AIBDs. To gain an in-depth understanding of CD4+ T-cell pathogenicity, antigen specificity, and mechanisms of immune tolerance, this review covers comprehensive mouse and human studies of pemphigus and bullous pemphigoid. Further exploration of pathogenic CD4+ T cells will potentially provide immune targets for improved treatment of AIBDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1161927

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic overview of immune mechanism of desmoglein (DSG)-specific CD4+ T cells in pemphigus. After recognizing DSG epitope expressed on major histocompatibility complex class II from medullary thymic epithelial cells under the control of AIRE, DSG-specific T cells undergo deletion in the thymus. When DSG-specific T cells escape from central tolerance, Tregs control tolerance in peripheral regions via OX40L-OX40 signaling. In a diseased state of pemphigus, tolerance is broken and DSG-specific CD4+ T cells become pathogenic. Of DSG-specific CD4+ T cells, ICOS+ Tfh cells interact with DSG-specific B cells to provide stimulatory signals including CD40L-CD40 interaction and cytokines. These signals lead to B-cell activation and proliferation, differentiation into plasma cells, and production of pathogenic DSG-specific IgG antibodies that induce acantholytic blister by loss of cell-cell adhesion in keratinocytes.
Figure 1 Schematic overview of immune mechanism of desmoglein (DSG)-specific CD4+ T cells in pemphigus. After recognizing DSG epitope expressed on major histocompatibility complex class II from medullary thymic epithelial cells under the control of AIRE, DSG-specific T cells undergo deletion in the thymus. When DSG-specific T cells escape from central tolerance, Tregs control tolerance in peripheral regions via OX40L-OX40 signaling. In a diseased state of pemphigus, tolerance is broken and DSG-specific CD4+ T cells become pathogenic. Of DSG-specific CD4+ T cells, ICOS+ Tfh cells interact with DSG-specific B cells to provide stimulatory signals including CD40L-CD40 interaction and cytokines. These signals lead to B-cell activation and proliferation, differentiation into plasma cells, and production of pathogenic DSG-specific IgG antibodies that induce acantholytic blister by loss of cell-cell adhesion in keratinocytes.CC BY · PubMed Central
Figure 2 Schematic overview of immune mechanism of BPAG-specific CD4+ T cells in bullous pemphigoid (BP). The triggering factor for BP can be medication (e.g., immune checkpoint inhibitors and dipeptidyl peptidase-4 inhibitor) or neurologic diseases. The process begins with the presentation of a BPAG epitope by dendritic cells through MHC class II, including HLA-DQB*03:01, which activates BPAG-specific CD4+ T cells. Also, dysfunction of Treg cells play a role in the development of BP, as evidenced in patients with IPEX syndrome. This leads to interaction with BPAG-specific B cells through CD40-CD40L interaction, resulting in the differentiation of B cells and the epitope spreading of IgG and IgE autoantibodies. Among them, NC16A domain of BPAG2 is recognized as a major pathogenic epitope of autoantibodies. These autoantibodies bind to the basement membrane zone of the skin and mucous membranes, inducing subepidermal blistering in BP. The increased type 2 immunity was seen in BP and might contribute to the development of the diseases.
Figure 2 Schematic overview of immune mechanism of BPAG-specific CD4+ T cells in bullous pemphigoid (BP). The triggering factor for BP can be medication (e.g., immune checkpoint inhibitors and dipeptidyl peptidase-4 inhibitor) or neurologic diseases. The process begins with the presentation of a BPAG epitope by dendritic cells through MHC class II, including HLA-DQB*03:01, which activates BPAG-specific CD4+ T cells. Also, dysfunction of Treg cells play a role in the development of BP, as evidenced in patients with IPEX syndrome. This leads to interaction with BPAG-specific B cells through CD40-CD40L interaction, resulting in the differentiation of B cells and the epitope spreading of IgG and IgE autoantibodies. Among them, NC16A domain of BPAG2 is recognized as a major pathogenic epitope of autoantibodies. These autoantibodies bind to the basement membrane zone of the skin and mucous membranes, inducing subepidermal blistering in BP. The increased type 2 immunity was seen in BP and might contribute to the development of the diseases.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Cited by

See all 13

Metadata

Authors
Lee, A. Y., Kim, T., & Kim, J. H.
Affiliations
Yonsei University (KR)
Corresponding author
Kim, Jong Hoon
Venue
Frontiers in Immunology
Published
2023-04-17
Volume
14
Pages
1161927-1161927
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4366227066
Cited by
13
References
79
Citations by year
2026: 4 · 2025: 4 · 2024: 4 · 2023: 1
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Korea Drug Development Fund (RS-2022-00165917)
Topics
  • Health Sciences › Medicine › Dermatology › Autoimmune Bullous Skin Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Skin and Cellular Biology Research
Keywords
autoimmune blistering disease, CD4+ T cells, autoantibodies, pemphigus, bullous pemphigoid, humoral immune response, immune tolerance, antigen specificity, blistering skin disease
MeSH terms
Animals, Autoantibodies, Autoimmune Diseases, Humans, Skin Diseases, Vesiculobullous, T-Lymphocytes, CD4-Positive T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding CD4+ T cells in autoimmune bullous diseases. https://app.cochat.ai/papers/10.3389/fimmu.2023.1161927
The paper
Lee, A. Y., Kim, T., & Kim, J. H. (2023). Understanding CD4+ T cells in autoimmune bullous diseases. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1161927

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.